13774
document
Evaluation of the effect of acetazolamide on cystoid macular oedema in patients with Behcet 's disease . AIM To study the effect of acetazolamide on cystoid macular oedema ( CMO ) in patients with Behcet 's disease . PATIENTS AND METHODS A total of 67 eyes of 35 Behcet 's patients with chronic , but well-controlled uveitis , and CMO were randomised into a double-masked , crossover trial comparing the effect of acetazolamide vs placebo . The patients received an initial 4-week course of either 250 mg acetazolamide twice daily ( b.i.d . ) or placebo , followed by a 4-week washout period . They then received a 4-week course of the reverse study medication . An improvement in visual acuity and fundus fluorescein angiographic findings was assessed . RESULTS In total , 29 patients ( 55 eyes ) completed the trial and were available for analysis . Of the 29 , 16 men and 13 were women . The age range was 13-50 years ( mean 33.6 years ) . Patients on acetazolamide showed a slightly better improvement of angiographic signs ( at least by one grade improvement ) over that of placebo ( 12 vs five eyes ) . They also had less deterioration of angiographic signs over that of placebo ( three vs seven eyes ) . However , these findings were not statistically significant ( P=0.99 ) . Acetazolamide had no statistically significant effect ( P=0.53 ) on the improvement of visual acuity of patients over that of placebo ( 13 vs eight eyes ) , nor on the deterioration of visual acuity ( three vs 11 eyes ) . CONCLUSION Despite seemingly favourable results , the 4-week course of acetazolamide ( 250 mg b.i.d . ) has no statistically significant effect on the improvement of the visual acuity and the fluorescein angiographic findings in Behcet 's patients with CMO .
13775
Intervention_Pharmacological
acetazolamide
13776
Intervention_Pharmacological
acetazolamide
13777
Intervention_Pharmacological
acetazolamide
13778
Intervention_Pharmacological
acetazolamide
13779
Intervention_Control
placebo
13780
Intervention_Pharmacological
acetazolamide
13781
Intervention_Control
placebo
13782
Intervention_Control
placebo
13783
Intervention_Pharmacological
Acetazolamide
13784
Intervention_Control
placebo
13785
Intervention_Pharmacological
acetazolamide
13786
Outcome_Physical
visual acuity
13787
Outcome_Physical
fundus fluorescein angiographic findings
13788
Outcome_Physical
angiographic signs
13789
Outcome_Physical
deterioration of angiographic signs
13790
Outcome_Physical
visual acuity
13791
Outcome_Physical
visual acuity
13792
Outcome_Physical
fluorescein angiographic findings
13793
Participant_Condition
cystoid macular oedema
13794
Participant_Condition
Behcet 's disease
13795
Participant_Condition
Behcet 's disease
13796
Participant_Sample-size
67 eyes of 35 Behcet 's patients
13797
Participant_Condition
chronic , but well-controlled uveitis , and CMO
13798
Participant_Sample-size
16
13799
Participant_Sex
men
13800
Participant_Sample-size
13
13801
Participant_Sex
women
13802
Participant_Age
13-50 years
13803
Participant_Age
33.6
13804
Participant_Condition
Behcet 's